In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features
Citations Over Time
Abstract
Abstract Deregulated signalling through phosphatidylinositol 3‐kinase ( PI 3K) pathway plays a critical role in tumour initiation and progression. We have already shown that AKT is activated in skin lesions in Mycosis Fungoides ( MF ) and we herein further investigate the frequency and clinical significance of PTEN and PI 3K at the protein and at the DNA level as well as the presence of AKT 1 mutations in skin lesions from 50 patients with MF clinical stages I‐ IV in relation to clinicopathological features. Increased p‐ AKT expression correlated with poor prognosis in plaques ( P = 0.0198), whereas p‐ AKT was an independent predictor of poor survival in the entire cohort ( P = 0.017, HR = 1.012). PTEN cytoplasmic expression was found low or absent in all 77.3% of cases and inversely correlated with advanced clinical stages ( P = 0.0744). Molecular analysis showed no AKT 1 mutation, no PI 3 KCA copy number gain, only 1 case with PI 3 KCA mutation in exon 9 and 3 cases with PTEN mutations (7%) in exons 7, 8 and 5. The latter correlated with disease ( P = 0.0253) and progression ( P < 0.0001) free survival in tumour stage. Although activation of PI 3K/ AKT signalling pathway due to PTEN alterations is rarely attributed to abnormalities in PTEN , PI 3K, and AKT 1 genes, PTEN mutations exert a negative effect on patients’ prognosis with tumours.
Related Papers
- → Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions(2023)135 cited
- → Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/Akt pathways(2019)95 cited
- → MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN(2018)75 cited
- → Akt as a therapeutic target in cancer(2008)140 cited
- → Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors(2012)27 cited